Angiotensin II induces skin fibrosis: a novel mouse model of dermal fibrosis

Arthritis Research and Therapy

Volumn 14, Issue 4, 2012, Pages

  Stawski, Lukasz ^a   Han, Rong ^a   Bujor, Andreea M ^a   Trojanowska, Maria ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; CALVASCULIN; CD3 ANTIGEN; CD45 ANTIGEN; CELL PROTEIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN EMR1; PROTEIN MAC3; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; C57BL 6 MOUSE; CELL INFILTRATION; COLLAGEN SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; FIBROGENESIS; HEART MUSCLE FIBROSIS; HUMAN; HUMAN CELL; INFLAMMATION; KIDNEY FIBROSIS; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SKIN FIBROSIS; SYSTEMIC SCLEROSIS; ANIMAL; C57BL MOUSE; CELL CULTURE; CHEMICALLY INDUCED; DISEASE MODEL; FIBROSIS; IMMUNOLOGY; PATHOLOGY; SKIN DISEASE;

ANGIOTENSIN II; ANIMALS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FIBROSIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; SKIN DISEASES;

EID: 84865186839     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4028     Document Type: Article

References (47)

1. Trojanowska M. Cellular and molecular aspects of vascular dysfunction in systemic sclerosis. Nat Rev Rheumatol 2010, 6:453-460. 10.1038/nrrheum.2010.102, 20585340.
2. Koenig M, Joyal F, Fritzler MJ, Roussin A, Abrahamowicz M, Boire G, Goulet JR, Rich E, Grodzicky T, Raymond Y, Senécal JL. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum 2008, 58:3902-3912. 10.1002/art.24038, 19035499.
3. Meyer M, Muller AK, Yang J, Sulcova J, Werner S. The role of chronic inflammation in cutaneous fibrosis: fibroblast growth factor receptor deficiency in keratinocytes as an example. J Invest Dermatol Symp Proc 2011, 15:48-52.
4. Zaman MA, Oparil S, Calhoun DA. Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 2002, 1:621-636. 10.1038/nrd873, 12402502.
5. Mezzano SA, Ruiz-Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension 2001, 38:635-638. 10.1161/hy09t1.094234, 11566946.
6. Brecher P. Angiotensin II and cardiac fibrosis. Trends Cardiovasc Med 1996, 6:193-198. 10.1016/S1050-1738(96)00072-2, 21232296.
7. Kawaguchi Y, Takagi K, Hara M, Fukasawa C, Sugiura T, Nishimagi E, Harigai M, Kamatani N. Angiotensin II in the lesional skin of systemic sclerosis patients contributes to tissue fibrosis via angiotensin II type 1 receptors. Arthritis Rheum 2004, 50:216-226. 10.1002/art.11364, 14730619.
8. Min LJ, Cui TX, Yahata Y, Yamasaki K, Shiuchi T, Liu HW, Chen R, Li JM, Okumura M, Jinno T, Wu L, Iwai M, Nahmias C, Hashimoto K, Horiuchi M. Regulation of collagen synthesis in mouse skin fibroblasts by distinct angiotensin II receptor subtypes. Endocrinology 2004, 145:253-260.
9. Pignone A, Rosso AD, Brosnihan KB, Perfetto F, Livi R, Fiori G, Guiducci S, Cinelli M, Rogai V, Tempestini A, Bartoli F, Generini S, Ferrario CM, Cerinic MM. Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 2007, 66:1305-1310. 10.1136/ard.2006.064493, 1994289, 17360781.
10. Batteux F, Kavian N, Servettaz A. New insights on chemically induced animal models of systemic sclerosis. Curr Opin Rheumatol 2011, 23:511-518. 10.1097/BOR.0b013e32834b1606, 21857225.
11. Wu M, Varga J. In perspective: murine models of scleroderma. Curr Rheumatol Rep 2008, 10:173-182. 10.1007/s11926-008-0030-9, 18638424.
12. Artlett CM. Animal models of scleroderma: fresh insights. Curr Opin Rheumatol 2010, 22:677-682. 10.1097/BOR.0b013e32833e307b, 20720495.
13. Derrett-Smith EC, Denton CP, Sonnylal S. Animal models of scleroderma: lessons from transgenic and knockout mice. Curr Opin Rheumatol 2009, 21:630-635. 10.1097/BOR.0b013e32833130c1, 19730378.
14. Smith GP, Chan ES. Molecular pathogenesis of skin fibrosis: insight from animal models. Curr Rheumatol Rep 2010, 12:26-33. 10.1007/s11926-009-0080-7, 2861786, 20425530.
15. Beyer C, Schett G, Distler O, Distler JH. Animal models of systemic sclerosis: prospects and limitations. Arthritis Rheum 2010, 62:2831-2844. 10.1002/art.27647, 20617524.
16. Bataller R, Sancho-Bru P, Gines P, Brenner DA. Liver fibrogenesis: a new role for the renin-angiotensin system. Antioxid Redox Signal 2005, 7:1346-1355. 10.1089/ars.2005.7.1346, 16115040.
17. Samuel CS. Determination of collagen content, concentration, and sub-types in kidney tissue. Methods Mol Biol 2009, 466:223-235. 10.1007/978-1-59745-352-3_16, 19148607.
18. Richard L, Velasco P, Detmar M. Isolation and culture of microvascular endothelial cells. Methods Mol Med 1999, 18:261-269.
19. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005, 7:156-162. 10.1007/s11926-005-0069-9, 15760596.
20. Ho MK, Springer TA. Tissue distribution, structural characterization, and biosynthesis of Mac-3, a macrophage surface glycoprotein exhibiting molecular weight heterogeneity. J Biol Chem 1983, 258:636-642.
21. Sulahian TH, Högger P, Wahner AE, Wardwell K, Goulding NJ, Sorg C, Droste A, Stehling M, Wallace PK, Morganelli PM, Guyre PM. Human monocytes express CD163, which is upregulated by IL-10 and identical to p155. Cytokine 2000, 12:1312-1321. 10.1006/cyto.2000.0720, 10975989.
22. Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N, Takeya M. AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem 2006, 54:763-771. 10.1369/jhc.5A6871.2006, 16517975.
23. Quan TE, Cowper SE, Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006, 8:145-150. 10.1007/s11926-006-0055-x, 16569374.
24. Kizu A, Medici D, Kalluri R. Endothelial-mesenchymal transition as a novel mechanism for generating myofibroblasts during diabetic nephropathy. Am J Pathol 2009, 175:1371-1373. 10.2353/ajpath.2009.090698, 2751533, 19729485.
25. Zeisberg EM, Tarnavski O, Zeisberg M, Dorfman AL, McMullen JR, Gustafsson E, Chandraker A, Yuan X, Pu WT, Roberts AB, Neilson EG, Sayegh MH, Izumo S, Kalluri R. Endothelial-to-mesenchymal transition contributes to cardiac fibrosis. Nat Med 2007, 13:952-961. 10.1038/nm1613, 17660828.
26. Li J, Qu X, Bertram JF. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am J Pathol 2009, 175:1380-1388. 10.2353/ajpath.2009.090096, 2751535, 19729486.
27. Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, Liu B. Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells. Cardiovasc Diabetol 2010, 9:31. 10.1186/1475-2840-9-31, 2920267, 20663195.
28. Pereira RM, dos Santos RA, da Costa Dias FL, Teixeira MM, Simoes e Silva AC. Renin-angiotensin system in the pathogenesis of liver fibrosis. World J Gastroenterol 2009, 15:2579-2586. 10.3748/wjg.15.2579, 2691487, 19496186.
29. Kuba K, Imai Y, Penninger JM. Angiotensin-converting enzyme 2 in lung diseases. Curr Opin Pharmacol 2006, 6:271-276. 10.1016/j.coph.2006.03.001, 16581295.
30. Rosenkranz S. TGF-beta1 and angiotensin networking in cardiac remodeling. Cardiovasc Res 2004, 63:423-432. 10.1016/j.cardiores.2004.04.030, 15276467.
31. Gabriel VA. Transforming growth factor-beta and angiotensin in fibrosis and burn injuries. J Burn Care Res 2009, 30:471-481. 10.1097/BCR.0b013e3181a28ddb, 19349880.
32. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?. Matrix Biol 2002, 21:473-482. 10.1016/S0945-053X(02)00055-0, 12392758.
33. Liu S, Taghavi R, Leask A. Connective tissue growth factor is induced in bleomycin-induced skin scleroderma. J Cell Commun Signal 2010, 4:25-30. 10.1007/s12079-009-0081-3, 2821481,2821481, 19916059.
34. Yamamoto T, Nishioka K. Cellular and molecular mechanisms of bleomycin-induced murine scleroderma: current update and future perspective. Exp Dermatol 2005, 14:81-95. 10.1111/j.0906-6705.2005.00280.x, 15679577.
35. Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro LA. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006, 126:1900-1908. 10.1038/sj.jid.5700302, 16691201.
36. Murray PJ, Wynn TA. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 2011, 11:723-737. 10.1038/nri3073, 3422549, 21997792.
37. Ikezumi Y, Suzuki T, Karasawa T, Hasegawa H, Yamada T, Imai N, Narita I, Kawachi H, Polkinghorne KR, Nikolic-Paterson DJ, Uchiyama M. Identification of alternatively activated macrophages in new-onset paediatric and adult immunoglobulin A nephropathy: potential role in mesangial matrix expansion. Histopathology 2011, 58:198-210. 10.1111/j.1365-2559.2011.03742.x, 21323947.
38. Higashi-Kuwata N, Makino T, Inoue Y, Takeya M, Ihn H. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma. Exp Dermatol 2009, 18:727-729. 10.1111/j.1600-0625.2008.00828.x, 19320738.
39. Phillips RJ, Burdick MD, Hong K, Lutz MA, Murray LA, Xue YY, Belperio JA, Keane MP, Strieter RM. Circulating fibrocytes traffic to the lungs in response to CXCL12 and mediate fibrosis. J Clin Invest 2004, 114:438-446. 484979, 15286810.
40. Okada H, Kalluri R. Cellular and molecular pathways that lead to progression and regression of renal fibrogenesis. Curr Mol Med 2005, 5:467-474. 10.2174/1566524054553478, 16101477.
41. Kisseleva T, Uchinami H, Feirt N, Quintana-Bustamante O, Segovia JC, Schwabe RF, Brenner DA. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006, 45:429-438. 10.1016/j.jhep.2006.04.014, 16846660.
42. Krenning G, Zeisberg EM, Kalluri R. The origin of fibroblasts and mechanism of cardiac fibrosis. J Cell Physiol 2010, 225:631-637. 10.1002/jcp.22322, 3098503, 20635395.
43. Mathai SK, Gulati M, Peng X, Russell TR, Shaw AC, Rubinowitz AN, Murray LA, Siner JM, Antin-Ozerkis DE, Montgomery RR, Reilkoff RA, Bucala RJ, Herzog EL. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype. Lab Invest 2010, 90:812-823. 10.1038/labinvest.2010.73, 20404807.
44. Tourkina E, Bonner M, Oates J, Hofbauer A, Richard M, Znoyko S, Visconti RP, Zhang J, Hatfield CM, Silver RM, Hoffman S. Altered monocyte and fibrocyte phenotype and function in scleroderma interstitial lung disease: reversal by caveolin-1 scaffolding domain peptide. Fibrogenesis Tissue Repair 2011, 4:15. 10.1186/1755-1536-4-15, 3155832, 21722364.
45. Tang RN, Lv LL, Zhang JD, Dai HY, Li Q, Zheng M, Ni J, Ma KL, Liu BC. Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. Int J Cardiol 2011,
46. Hashimoto N, Phan SH, Imaizumi K, Matsuo M, Nakashima H, Kawabe T, Shimokata K, Hasegawa Y. Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2010, 43:161-172. 10.1165/rcmb.2009-0031OC, 2937229, 19767450.
47. Xu H, Zaidi M, Struve J, Jones DW, Krolikowski JG, Nandedkar S, Lohr NL, Gadicherla A, Pagel PS, Csuka ME, Pritchard KA, Weihrauch D. Abnormal fibrillin-1 expression and chronic oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic sclerosis. Am J Physiol Cell Physiol 2011, 300:C550-C556. 10.1152/ajpcell.00123.2010, 3063974, 21160034.